semaglutide novo nordisk Nordisk's diabetes and weight loss drug sales growth decelerates Novo Nordisk study finds greater

The pill is the right choice for some patients and not for others

It can cause modest weight loss but requires a prescription

Key markers include fasting glucose and insulin (to assess insulin sensitivity), HbA1c (long-term glucose regulation), lipid panel (triglycerides, HDL, LDL), resting metabolic rate via indirect calorimetry, and body composition via DEXA scan (to differentiate fat loss from lean mass changes)

However, this observed weight loss effect has led to complex market dynamics and accessibility challenges due to widespread off-label use, sometimes up to five t 10% of body weight. Wegovy: Specifically designed to target the obesity pathway, Wegovy (up to 2.4mg weekly vs

Participants will receive 15 mg tirzepatide subcutaneously once-weekly (dose escalation period of 20 weeks) for up to 84 weeks